Good morning, Boston. Here are the five things you need to know in Boston business news to start your workday.
Low on cash, Axcella pursues Long Covid drug
Axcella Therapeutics Inc. has one of the most advanced potential drugs for Long Covid. But it has only enough cash to get it through the second quarter of this year, making for a mad-dash effort to get that drug through clinical trials, Rowan Walrath reports.
Microbiome startup cuts 95% of remaining staff
Rowan also reports that Finch Therapeutics…
